Ms Cheryl Dianne Planert, LMFT | |
530 First St., Se, Beach, ND 58621 | |
(701) 872-2667 | |
Not Available |
Full Name | Ms Cheryl Dianne Planert |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 530 First St., Se, Beach, North Dakota |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205145232 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | 6 (North Dakota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ms Cheryl Dianne Planert, LMFT Po Box 982, 530 First St., Se, Beach, ND 58621-0982 Ph: (701) 872-2667 | Ms Cheryl Dianne Planert, LMFT 530 First St., Se, Beach, ND 58621 Ph: (701) 872-2667 |
News Archive
Brazilian researchers, reporting in the current issue of Cell Transplantation, discovered difficulties in establishing a genetically diverse line of human embryonic stem cells to serve the therapeutic stem cell transplantation needs of the diverse ethnic and genetic Brazilian population.
Practicing Clinicians Exchange (PCE) has formed a partnership with the National Psoriasis Foundation (NPF) to provide continuing education programs to nurse practitioners (NPs) and physician assistants (PAs) throughout the United States.
As the health care debate grinds forward, Majority Leader Harry Reid asked a group of ten Democratic senators - five liberals and five centrists - to forge a compromise on a government-operated health insurer, The New York Times reports. Even among Democrats, moderates and liberals differ on this thorny issue. "The push for a deal on the public option indicated the pressure Democrats were feeling to resolve their differences if they hope to pass the bill by their self-imposed deadline of Christmas" (Pear and Herszenhorn, 12/6).
Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.
Adherence to interferon, an important medication used to treat Hepatitis C, is critical to successfully clearing the virus that causes the disease. A new observational analysis by Medco Health Solutions, Inc. finds that when Hepatitis C patients are also being treated for depression - a frequent side effect of interferon use - they are more likely to remain on their interferon therapy.
› Verified 5 days ago